Prognosis – Risk – Treatment Response

Quantitative Textural Analysis

Clinical Decision Support – A potential new tool for clinical decision makers, TexRAD may optimise care pathways, improve patient outcomes and offer cost-effective patient management.

Analyse Textures – TexRAD detects and measures ‘tumour complexity’ in medical images and reveals more information than is readily visible to the naked eye.

Score and Compare – The Data Miner then allows you to risk stratify measurable textures between tumours and subjects.

Imaging Biomarkers – Using quantitative textural analysis, TexRAD may provide a new imaging biomarker for heterogeneity to add value to existing markers of tumour size, density and perfusion.

Currently, doctors rely on medical imaging to make decisions on patient care and treatment, but these are limited to what can be seen by the human eye. TexRAD measures textures in CT and MRI that we may not otherwise recognise. It measures heterogeneity and allows comparisons between samples, subjects and time periods meaning cancer treatments can be better tailored to patient needs.

Our long term goal is to use TexRAD to support early diagnosis in cancer and other diseases and long term conditions such as dementia, and to enable early interventions and reduce disease progression.

Primary Software Features

PACS connectivity

Full DICOM compliance means TexRAD fits with existing clinical workflow

Web based analysis

TexRAD can be delivered through a browser to anyone on your network

Data Miner

The real power of textural analysis is released when you compare each new result with existing images and known outcomes

Existing datasets

TexRAD uses existing images acquired in the normal course. You can analyse historic images and build a comprehensive dataset over time

What does TexRAD do?

TexRAD is an innovative algorithm that quantifies textures in medical images.

Current treatment decisions for patients with cancer are primarily based on the extent of tumour spread (i.e. tumour stage). Diagnostic imaging, especially CT and PET are essential to determining the stage for many cancers. But as everyone knows, patients with the same tumour stage often follow differing clinical courses and may benefit from different treatments.

There is a need for new methods of assessing cancer so that treatments can be selected to more closely match the likely clinical course. Medical images such as CT scans and MRI scans are used to make decisions on patient care and treatment but are limited to what the human eye can see.

Diagnostic imaging systems have generally enhanced fine detail (i.e. high spatial frequency information) with the aim of optimising anatomical resolution. TexRAD finds important discriminatory information is to be found within coarser variations in image brightness (i.e. lower spatial frequencies). These variations can be perceived as abnormalities of texture.

TexRAD’s proprietary technology highlights these coarser features and uses histogram analysis to quantify and assess the distribution of grey-levels, coarseness and regularity within a lesion. By using filters that extract and enhance for image features at larger scales, the effect of noise is reduced whilst biological heterogeneity is enhanced.

TexRAD allows heterogeneity parameters measured at different spatial scales to be compared and presented as ‘texture ratios’ or ‘texture spectra’ enabling quantitative assessment of imaging biomarkers within a tumour and which can potentially be used to compare and stratify for risk, prognosis and treatment response.

TexRAD has been used to retrospectively analyse images from a wide range of conditions including colorectal, breast, lung, prostate, oesophageal, head and neck, and renal cancers.

TexRAD Research software is NOT a medical device, and as such there should be no reliance on the outputs of the software for any clinical purpose, or to make any clinical decisions.